Laboratories - the forgotten stakeholder
"Pathologists and laboratories are often overlooked as key stakeholders by pharma and this factor can have a considerable impact on the uptake of targ...
Jordan Clark and Ryan Keeling of Diaceutics appreciate the difficulties in determining the unknown costs of a diagnostic program, but are on hand with advice and solutions to successfully guide you through the budgeting process.
As a project leader or executive on a therapy team, you may find that determining the unknown costs of your precision/personalized medicine diagnostic program is challenging. You may be confused about what budget to allocate and when. We at Diaceutics sympathize.
So let’s see if we can help in these easy steps.
The specific method we use to help our clients can do just that and figure out what their diagnostic runway needs will be in terms of time and investment. As a rule of thumb it costs $50m to commercially align testing with a targeted therapy. Thirty-five per cent of that should be spent pre-launch to build the runway and 65 per cent should help with accelerating testing after take-off.
We can go further than that though and help you link specific investments in better testing with return on patients treated. Executed well, the return on investment is superior to most other commercial stage investments, whereas late or insufficient investment in testing can create a barrier to therapy access.
If you are planning your budgets for 2017 and wondering what and where to invest, give yourself 30 minutes to take the PM Readiness test and read the Expert Insights, then call Diaceutics to see if we can help. We’re confident we can.